2018
Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies
Han X, Vesely MD. Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. International Review Of Cytology 2018, 342: 1-25. PMID: 30635089, PMCID: PMC6487201, DOI: 10.1016/bs.ircmb.2018.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsT cellsT-lymphocyte antigen-4Monoclonal antibodiesInhibitory T cell receptorsCostimulatory receptor CD137Immunostimulatory monoclonal antibodiesUse of immunotherapeuticsT cell receptorAntitumor immunityDeath-1Antigen-4Immune surveillanceAgonist antibodyCostimulatory receptorsF. Macfarlane BurnetCancer cellsAntibodiesCancerReceptorsMacfarlane BurnetCellsGITRCD137CD27OX40
2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.Peer-Reviewed Original Research
2012
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.Peer-Reviewed Original ResearchConceptsIL-12IL-23Antibody treatmentImmune systemCD40 antibody treatmentIL‐12/23p40 antibodiesAutoimmune inflammatory disorderMonoclonal antibody treatmentOccult neoplasiaOccult cancerIL-17IL-23p19IL-12/23p40Immune controlInflammatory disordersTumor immunogenicityIL-4Malignant potentialCancer immunoeditingTumor outgrowthElimination phaseTumor growthTumor dormancyMutant cancersCancer cells